Abstract
Aim: To prove if a nutraceutical containing Ilex paraguariensis (Ilex L. spp. Aquifoliales) (an extract of the leaf standardized to 2% I-deoxinojirimcina), white mulberry (Morus spp., Moraceae), and chromium picolinate can be effective in improving glycemic status in subject with dysglycemia. Methods: We randomized patients to consume placebo or the nutraceutical, self-administered once a day, one tablet at breakfast, for 3 months. Results: A reduction in fasting plasma glucose, postprandial glucose, and glycated hemoglobin was observed with the nutraceutical combination, both compared to baseline and placebo. Data suggested a decrease in the Homeostasis Model Assessment index with the nutraceutical, both compared to baseline and placebo. The M value, an index of insulin sensitivity, obtained after nutraceutical treatment was higher compared to baseline. We recorded a decrease in total cholesterol, low-density lipoprotein-cholesterol, and triglycerides with the nutraceutical combination compared to baseline and placebo. A decrease in high-sensitivity C-reactive protein was observed with the nutraceutical combination compared to baseline and placebo. Conclusions: A nutraceutical containing Ilex paraguariensis, white mulberry, and chromium picolinate can be helpful in improving glycemic status and lipid profile in dysglycemic subjects.
Highlights
The first patient was enrolled on 1 October 2018, while the last patient was enrolled on 31 May 2019
After 3 months, 25.3% of subjects returned to a normal glycemic status in the nutraceutical group vs. 0 patients in the placebo group (p < 0.05)
We recorded that a nutraceutical containing Ilex paraguariensis, white mulberry, and chromium picolinate improved glycemic status in dysglycemic patients and, in particular, reduced fasting plasma glucose (FPG), PPG, and HbA1c
Summary
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. The condition of euglycemia is characterized by levels of fasting plasma glucose (FPG). Euglycemia is usually maintained by the balance of two antagonist hormones: glucagon, with a glucose-elevating action, secreted by pancreatic α-cells; and insulin, with a glucose-lowering effect, produced, instead, by pancreatic β-cells. Adipose tissue, and liver cells have receptors for insulin and glucagon
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
